- Home
- WATT vs LIPO Comparison
WATT vs LIPO Comparison
Compare WATT & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- LIPO
- Stock Information
- Founded
- WATT 2012
- LIPO 2005
- Country
- WATT United States
- LIPO United States
- Employees
- WATT N/A
- LIPO N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- LIPO Health Care
- Exchange
- WATT Nasdaq
- LIPO Nasdaq
- Market Cap
- WATT 3.9M
- LIPO 3.2M
- IPO Year
- WATT 2014
- LIPO 2022
- Fundamental
- Price
- WATT $0.61
- LIPO $0.48
- Analyst Decision
- WATT Strong Buy
- LIPO Strong Buy
- Analyst Count
- WATT 2
- LIPO 1
- Target Price
- WATT $2.25
- LIPO $2.00
- AVG Volume (30 Days)
- WATT 133.2K
- LIPO 2.6M
- Earning Date
- WATT 11-07-2024
- LIPO 11-12-2024
- Dividend Yield
- WATT N/A
- LIPO N/A
- EPS Growth
- WATT N/A
- LIPO N/A
- EPS
- WATT N/A
- LIPO N/A
- Revenue
- WATT $370,184.00
- LIPO $507,204.00
- Revenue This Year
- WATT $95.75
- LIPO N/A
- Revenue Next Year
- WATT $834.07
- LIPO N/A
- P/E Ratio
- WATT N/A
- LIPO N/A
- Revenue Growth
- WATT N/A
- LIPO 34.99
- 52 Week Low
- WATT $0.54
- LIPO $0.32
- 52 Week High
- WATT $2.75
- LIPO $2.25
- Technical
- Relative Strength Index (RSI)
- WATT 48.13
- LIPO 56.19
- Support Level
- WATT $0.56
- LIPO $0.44
- Resistance Level
- WATT $0.61
- LIPO $0.52
- Average True Range (ATR)
- WATT 0.04
- LIPO 0.05
- MACD
- WATT 0.01
- LIPO 0.01
- Stochastic Oscillator
- WATT 69.60
- LIPO 73.29
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.